GLP-1 Drug Use Surges 600% as 2% of Americans Take Weight-Loss Medications
An anonymous reader shares a report: More than 2% of Americans are taking the blockbuster class of GLP-1 drugs for overweight or obesity, up nearly 600% over six years, according to a report from FAIR Health given to Axios first. The data from FAIR Health’s repository of over 51 billion commercial healthcare claim records shows […]
What’s the Price Outlook for Weight-Loss Drugs?
The supply of GLP-1 drugs like Ozempic has been increasing, but they’re still expensive for most patients. Here are answers to some questions consumers have. Continuing high prices and demand for GLP-1 weight-loss drugs is creating lots of questions about the affordability of these drugs for U.S. …
Mochi Health Launches Insurance-Based Plans, Expanding Access to Personalized Obesity Care with Behavioral Therapy
What You Should Know: – Mochi Health, a physician-guided obesity care program, announced the launch of its new insurance-based plans. – These expanded offerings are designed to provide more personalized treatment experiences for patients, placing a strong emphasis on comprehensive obesity care that spans all aspects of an individual’s health. – The new insurance-based plans […]
Comedian Jim Gaffigan admits he lost 50 pounds using Mounjaro
Jim Gaffigan shared his weight loss journey with Mounjaro, as he shed 50 pounds. Celebrities like Rosie O’Donnell and Amy Schumer also credited the diabetes drug.
GLP-1 prescriptions surge in US: 7 study notes
In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records. Fair Health also found that, over those six years, the percentage of adults with a GLP-1 prescription for obesity or overweight increased […]
The role of GLP-1 receptor agonists in the management of obesity
As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights into the rapidly evolving use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as Ozempic in the Australian health care system.
Fractyl Rejuva GLP-1 Gene Therapy Data at ASGCT 2025
The sources discuss Fractyl Health’s Rejuva GLP-1 gene therapy platform, highlighting preclinical data presented at ASGCT 2025 for its candidate RJVA-001. This research indicates that a single dose of RJVA-001 in animal models durably improves metabolic markers related to type 2 diabetes and obesity, achieving similar effects as existing GLP-1 drugs but with significantly lower systemic exposure, potentially leading to fewer […]
GLP-1 drugs are life-changing — let’s remove their stigma
I have struggled with my weight my entire life — sometimes less successfully (hello, cooking school in Paris) and sometimes much more successfully. Prior to becoming pregnant, I can’t remember a single time in my life that I wasn’t on a diet or some special workout kick, or whatever it might be. This led me […]
The Dark And Light Side Of Ozempic: Here’s What Experts Say About The Popular Diet Medicine
Not that long ago, it was found that 1 in 8 adults in the United States has taken Ozempic or a similar medicine. While some of them take it for their diabetes, others, as you probably know, take it as a way to lose weight. This usage has become so common that some have dubbed […]
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
Post Content